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This year marks the centenary of the publica-
tion in the JEM (Rous, 1911) of one of the 
twentieth century’s most seminal discoveries in 
medical  research,  namely,  the  filterable  agent 
that  became  known  as  Rous  sarcoma  virus 
(RSV).  It  earned  the  discoverer,  F.  Peyton 
Rous (1879–1970; Fig. 1) the Nobel Prize in 
1966. Rous made his discovery at the Rocke-
feller  Institute,  as  the  University  was  then 
known, and he stayed there for the rest of his 
long and illustrious career. Why was the dis-
covery important and why did it take so long 
for Rous to achieve the ultimate accolade of a   
Nobel Prize?
Peyton Rous was born on October 5, 1879. 
His father died when he was still a child, leav-
ing his mother to raise three children on a mea-
ger income in Baltimore. As a youngster, Rous 
was fascinated by natural history. He studied at 
Johns Hopkins University, gaining his BA in 
1900 and his MD in 1905. After brief periods 
investigating  pathology  at  the  University  of 
Michigan and in Dresden, Germany, in 1909 
he was invited by Simon Flexner to join the 
Rockefeller Institute in New York, where he 
worked for the rest of his life.
Rous’s most famous discovery was finding 
that a sarcoma in the domestic fowl was trans-
missible to other fowl by a tumor extract that 
he had passed through a filter too fine to con-
tain chicken cells or bacteria. In other words, 
the tumor-inducing agent was a “virus,” which 
later became known as RSV. The importance 
of this finding was twofold. First, it demon-
strated clearly for the first time that a malignant 
tumor could be induced by infection. Many other 
examples of tumor-inducing viruses in rabbits, 
mice, cats, and nonhuman primates eventually 
followed  (Shope  and  Hurst,  1933;  Bittner, 
1942; Gross, 1951; Sweet and Hilleman, 1960), 
and the first oncogenic human virus, Epstein-
Barr virus, was observed in 1964 (Epstein et al., 
1964). Second, RSV represented a pioneer-
ing oncogenic retrovirus for investigating the   
molecular  mechanisms  of  cancer  develop-
ment (Kurth and Bannert, 2010). Studies from 
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The discovery of Rous sarcoma virus, which was reported by Peyton Rous in the Journal of 
Experimental Medicine 100 years ago, opened the field of tumor virology. It showed that 
some cancers have infectious etiology, led to the discovery of oncogenes, and laid the 
foundation for the molecular mechanisms of carcinogenesis. Rous spent his entire  
research career at the Rockefeller Institute, and he was the JEM’s longest serving editor. 
Here, we comment briefly on the life of this remarkable scientist and on the importance  
of his discoveries.
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Figure 1.  Peyton Rous in 1923. Reproduced with per-
mission from the Rockefeller University archives. Van Epps, 
2005. J. Exp. Med. http://dx.doi.org/10.1084/jem.2013fta
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“RNA tumor virus,” and after the discovery of reverse tran-
scription (Baltimore, 1970; Temin and Mizutani, 1970), the 
term “retrovirus” came into use. 60 years after the discovery 
of RSV, the first retroviral infection in a human was reported 
(Achong et al, 1971). This was a foamy virus that we now 
know represented a primary zoonotic infection from a chim-
panzee, and it is apparent that primate foamy retroviruses fre-
quently infect exposed humans (Switzer et al, 2004). It was 
not  until  1980  that  human  T  cell  leukemia  virus  type  I 
(HTLV-1) was found to be the first genuine human retro-
virus with oncogenic properties (Poiesz et al, 1980) causally   
associated with adult T cell lymphoma-leukemia (Yoshida   
et al., 1982). We currently know of four circulating human 
retroviruses (HTLV-1 and -2 and HIV-1 and -2); there have 
also been many false alarms (Voisset et al., 2008), the most 
recent of which was the apparent link of a xenotropic murine-
related retrovirus to human prostate cancer and to chronic 
fatigue syndrome ( Cohen and Enserink, 2011).
Today, we tend to regard retroviral infections as being 
ubiquitous among vertebrate species. While this may be the 
case with endogenous retroviral genomes that are transmit-
ted  as  Mendelian  genes  in  the  host  (Kurth  and  Bannert, 
2010), not all well-studied species harbor known retroviral 
pathogens. It is curious that no infectious retroviruses have 
been identified in dogs, whereas cats harbor leukemia viruses, 
immunodeficiency  viruses,  and  foamy  viruses.  The  most   
recently  discovered  oncogenic  retrovirus  is  the  infectious 
leukemia virus of the koala, a virus that is undergoing a pro-
cess of endogenization (Tarlinton et al., 2006).
It is interesting to return to the step by step progress of 
Rous’s research. Rous (1910) became interested in the trans-
plantability of tumors when a woman came to the Rocke-
feller Institute with a Plymouth Barred Rock hen with a large 
tumor (Fig. 2). At that time, highly inbred mice were not 
yet available, although Loeb (1901) had started to experi-
ment on tumor transplantation with a sarcoma in a partially 
inbred line of white rats. The canine transmissible venereal 
sarcoma  (Novinski,1876) was the only tumor to be naturally 
the late 1950s onwards, after a quantitative in vitro bioassay 
for RSV was devised by Temin and Rubin (1958), led to the 
identification of oncogenes, which were initially found in 
retroviruses (Toyoshima and Vogt, 1969; Duesberg and Vogt, 
1970; Martin, 1970) and were later found in cells (Stehelin   
et al., 1976).
The src oncogene of RSV became the prototype for doz-
ens of other transforming genes in oncogenic viruses. Onco-
genes function in cell signaling from growth factors, and their 
receptors function through signal transduction pathways to 
nuclear transcription factors. For example, the myc gene was 
first identified in an avian myelocytoma virus and the ras 
gene was first identified in rat sarcoma virus long before they   
became associated with human malignancies. The src gene 
product was identified by Brugge and Erikson (1977), and it 
was the first protein to be shown to be a tyrosine kinase 
(Hunter and Sefton, 1980). These oncogenes provide a gain-
of-function in cellular signaling, stimulating cell division and 
leading to malignant transformation. Not long after onco-
genes were discovered, DNA tumor viruses were shown to 
encode proteins that sequester cell proteins and induce their 
loss-of-function for controlling the cell cycle. The genes en-
coding these cell proteins became known as tumor suppressor 
genes. An example is p53, a transcription factor of 53 kD 
that was pulled down by immunoprecipitation of the poly-
oma virus SV40 protein large T (Lane and Crawford, 1979; 
Linzer and Levine, 1979). The binding of the large T protein 
to p53 leads to a loss of p53 transcriptional activity (Mietz   
et al., 1992).
The notion of transmissibility of tumors, however, pre-
dated Rous’s discovery. In 1842, Domenico Rigoni-Stern 
observed that nuns in Verona rarely developed cervical can-
cer, compared to its frequency in married women (Scotto 
and Bailar, 1969), although the causative papilloma virus was 
not identified until 1983 (Dürst et al., 1983). Similarly, Jaag-
siekte lung carcinoma in sheep was known to be transmis-
sible in the nineteenth century, yet the causative agent, the 
Jaagsiekte  retrovirus,  was  also  only  characterized  in  1983   
(Verwoerd et al., 1983).
The first filterable disease agent that we now classify as a 
retrovirus (lentivirus) was the equine infectious anemia virus 
(Vallée and Carré, 1904). In 1908, Ellerman and Bang (1908) 
of Denmark described a form of erythroleukemia in chickens 
that could be passed as a filterable agent. It represented the 
first example of an avian leukemia virus (ALV), but the ma-
lignant nature of leukemia was not generally recognized, and 
this important discovery did not have the impact of RSV. 
Even Rous’s findings were not at first thought to be of par-
ticular interest because a solid tumor in a bird was not con-
sidered to be a suitable model for mammalian cancer. Viruses 
were  thought  to  cause  acute  diseases  that  would  rapidly   
appear in the majority of infected individuals. That paradigm 
was different from our modern knowledge of viral oncogen-
esis and of persistent infections with long latency periods.
When  RSV  was  shown  to  contain  an  RNA  genome 
(Crawford and Crawford, 1961), it became the prototype 
Figure 2.  The original Plymouth Barred Rock fowl bearing the 
tumor presented to Rous and held by somewhat arthritic hands. 
Reproduced from Rous, 1910.JEM Vol. 208, No. 12  2353
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which was delivered 3 years before his death at the age of 90. 
Even the greatest scientists can have blind spots! Despite his 
beliefs, his discovery of viruses containing oncogenes and his 
studies of mutagenic chemical carcinogens are now seen as laying 
the foundation for our understanding of the multiple somatic 
genetic changes that occur in malignancy, as revealed by com-
plete sequencing of cancer cell genomes (Stratton, 2011).
In addition to his own research, Rous became the longest 
serving editor of the JEM, fulfilling this duty from 1922 until 
shortly before his death in 1970. In 1946, René Dubos joined 
him as an assistant editor. Dubos (1979) has said that Rous 
selected him for this duty after a lunchtime discussion on 
whether medicine was a science or an art. Dubos expressed 
the view that at the Rockefeller Institute all that mattered 
was that researcher have a “hunger for facts.” This enthusi-
asm for evidence-based medicine, as we now call it, epito-
mized Rous’s own attitude to research. As an editor, Rous 
championed clarity above elegance and preferred good plain 
English to long words of Latin origin.
Peyton Rous had to wait 55 years for his discovery to be 
recognized by the honor of a Nobel Prize, which is the long-
est “incubation period” in the 110 years history of the   
Nobel Prizes in Physiology or Medicine. One reason for 
this delay may have been that the immense importance of 
or experimentally transplantable across major histocompati-
bility barriers, even to foxes, but not by a filtrate (Sticker 
1906). Rous cites this transmissible venereal tumor of dogs, 
referred to as “Sticker’s lymphosarcoma,” in his 1910 paper, 
but it took an additional 100 years to firmly establish that the 
transmissible agent of the canine tumor is not a virus at all, 
but is actually the tumor cell itself (Murgia et al 2006).
Rous (1910) wrote: “In this paper is reported the first 
avian tumor that has proved transplantable to other individu-
als. It is a spindle-celled sarcoma of a hen, which has thus far 
has  been  propagated  to  the  fourth  generation.  This  was   
accomplished by the use of fowls of pure blood from the 
small, intimately related stock in which the growth occurred. 
Market bought fowls of the same variety have shown them-
selves insusceptible, as have fowls of mixed breed, pigeons and 
guinea-pigs.”
Some months later, however, Rous found that the tumor 
had greatly increased its transmissibility in chickens, and that 
was when he successfully tested a cell-free filtrate (Rous, 
1911). We can do no more than speculate with the hindsight 
of our greater knowledge of avian retroviruses why the fil-
trate did not take in diverse strains of chicken straight away. 
If the original strain of RSV was replication defective, requir-
ing a complementing ALV for propagation, then a different 
ALV strain in one of the birds through which it was passed 
may have provided the expansion of host range. Alternatively, 
the original tumor might have had an activated cellular src gene 
that only became incorporated into an ALV genome de novo 
during experimental passage.
Rous subsequently reported the isolation of two other 
transmissible avian tumors (Rous and Murphy 1914), as did 
Fujinami and Inamoto (1914) in Japan. Thus, the observation 
of an oncogenic chicken virus was not a one-off phenome-
non. Rous dropped the investigation of avian tumors at the 
onset of the First World War, when he became involved in 
pioneering work on blood transfusion and helped to es-
tablish the first blood banks in the USA. He did not return 
to his avian tumor work after the war; he may have been dis-
couraged by the lack of recognition of the discovery of RSV 
as an important one. However, Rous did maintain an interest 
in oncogenic viruses, and in the 1930s he encouraged his 
Rockefeller colleague, Richard Shope, to study the skin pap-
illomas of rabbits. Soon after Shope’s description of rabbit 
papilloma virus (Shope and Hurst, 1933), Rous embarked on 
a series of studies lasting nearly 30 years, in which he used the 
benign viral papillomas as a precursor to malignant tumors 
induced with chemical carcinogens (Rous and Beard 1935; 
Rous and Kidd, 1940; Rous et al., 1952). He was the first to 
conceptualize carcinogenesis as occurring in two distinct 
stages, initiation and progression, although it was Berenblum 
and Shubik (1947) who showed how effective nonmutagenic 
phorbol esters are in inducing tumor progression.
Curiously, Rous eschewed the idea that somatic muta-
tion was an essential route to cancer development (Rous, 
1959), and he stubbornly held onto his view that cancer is 
not a genetic disease in his Nobel lecture (Rous, 1967), 
Figure 3.  Cell transformation by RSV. (A) The RSV focus assay of 
transformed cells in a chick embryo fibroblast monolayer as described  
by Temin and Rubin (1958) showing a 1:100 and 1:1000 dilution of the 
virus stock. Each stained dot represents a focus of transformed cells.  
(B) A scanning electron micrograph of one focus of RSV-transformed cells. 
It was the ability to transform cells in culture and to isolate individual 
clones of RSV that led to the molecular biology and genetic studies of 
tumor viruses. (Reproduced from Weiss, R.A., PhD thesis, University of 
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his discovery was not evident until the 1960s, when a renais-
sance of RSV studies occurred thanks to the virus’s ability   
to transform cells in culture (Temin and Rubin, 1958; Fig. 3). 
But according to Norrby (2011), Rous was nominated on 
several occasions from 1929 onwards. Another reason for 
hesitation may have been the fact that the Nobel Committee 
had burnt its fingers with the award to the Danish physician, 
Johannes Fibiger, in 1926 for his discovery of an apparently 
oncogenic parasite in rats that later turned out to have no   
association with the tumor. In the aftermath of Fibiger’s Prize, 
the Nobel Committee may have been overly cautious, and 
no further Nobel Prizes in the field of cancer were awarded 
for 40 years until Rous was recognized alongside Charles 
Huggins, who had discovered the therapeutic role of steroid 
hormones in controlling certain cancers.
Times and attitudes have changed. RSV has earned later 
investigators two more Nobel Prizes: Howard M. Temin and 
David Baltimore in 1975, for the discovery of reverse tran-
scriptase (Temin and Mizutani, 1970; Baltimore 1970), and 
Harold E. Varmus and J. Michael Bishop in 1989, for the 
discovery of the cellular origin of the retroviral oncogenes 
exemplified by src (Stehelin et al, 1976). The Nobel Prize in 
Physiology or Medicine of 1976 went to Baruch Blumberg 
for the discovery of hepatitis B virus, a causative agent of   
hepatocellular carcinoma (London et al., 1969). Moreover, 
three novel infectious agents in humans that have a cancer 
association were each discovered in 1983—a vintage year for 
pathogen discovery (Weiss, 2008)—which led to Nobel rec-
ognition: Barry Marshall and Robin Warren in 2005 for their 
discovery of Helicobacter pylori (Marshall and Warren, 1984), 
and in 2008, jointly, Harald zur Hausen for identifying cer-
vical  human  papilloma  viruses  (Dürst  et  al.,  1983)  and 
Françoise Barré-Sinoussi and Luc Montagnier for isolating 
HIV (Barré-Sinoussi et al., 2004). Today, we appreciate that 
20% of the global burden of human cancer has an infec-
tious etiology (Parkin, 2006) for which preventive measures 
such as vaccines have great promise. Peyton Rous’s meticulous 
investigations on viral cancer, reported in the JEM 100 years 
ago, have had a mighty legacy indeed.
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